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ABSTRACT 
Background: Technological advances raise the possibility of systematic population-
based genetic testing for cancer predisposing mutations, but it is uncertain whether 
benefits outweigh its disadvantages. We directly compared the psychological/quality-
of-life consequences of such an approach to family-history (FH) based testing. 
 
Methods: In a randomized controlled trial of BRCA1/2 gene-mutation testing in the 
Ashkenazi-Jewish (AJ) population, we compared testing all participants in the 
Population-Screening (PS) arm with testing those fulfilling standard FH-based clinical 
criteria (FH arm). Following a targeted community campaign, AJ participants older 
than18years were recruited by self-referral after pre-test genetic-counseling.  The 
effects of BRCA1/2 genetic testing on acceptability, psychological impact and 
quality-of-life measures were assessed by random-effects regression analysis.  All 
statistical tests were two-sided.   
 
Results: 1168 AJ individuals were counseled, 1042 consented, 1034 were 
randomized (691 women, 343 men) and 1017 were eligible for analysis. Mean age 
was 54.3 (SD=14.66) years. Thirteen BRCA1/2 carriers were identified in the PS 
arm, 9 in the FH arm.  Five more carriers were detected among FH-negative FH-arm 
participants following study completion. There were no statistically significant 
differences between the FH and PS arms at 7 days or 3 months on measures of 
anxiety, depression, health anxiety, distress, uncertainty and quality of life. Contrast 
tests indicated that overall anxiety (p=0.0001), and uncertainty (p=0.0008) 
associated with genetic testing decreased; positive experience scores increased 
(p=0.0001); quality of life and health anxiety did not change with time. Overall, 56% 
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of carriers did not fulfill clinical criteria for genetic testing, and the BRCA1/2 
prevalence was 2.45%.  
 
Conclusion: Compared to FH-based testing, population-based genetic testing in 
Ashkenazi Jews doesn’t adversely affect short term psychological/quality-of-life 
outcomes and may detect 56% additional BRCA carriers. 
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INTRODUCTION 
 
Important advances in understanding germ-line predisposition to familial cancer have 
led to the identification of several rare high-penetrance genes causing cancer 
syndromes: BRCA1/BRCA2 (familial breast and/or ovarian cancer) and mismatch-
repair genes (Lynch Syndrome).  BRCA1/2 carriers have a 50%-80% risk of breast 
cancer, 20%-45% risk of ovarian cancer (OC) and 5%-25% risk of prostate 
cancer.[1-5] Established management strategies for high-risk individuals include: (a) 
risk-reducing salpingo-oophorectomy(RRSO) to prevent tubal/ovarian cancer (HR, 
0.21),[6] (which also halves breast cancer risk in pre-menopausal women),[6] (b) 
risk-reducing mastectomy to prevent breast cancer,[7-9]  (c) early onset breast 
screening (MRI/mammograms) and (d) pre-implantation genetic diagnosis. 
 
Within the UK National Health Service (NHS), genetic mutation testing is limited to 
individuals with cancer from high-risk families (carrier probability ≥20% in the general 
population and ≥10% in the Jewish population) or individuals from families with a 
confirmed BRCA mutation who request referral to specialist genetic clinics. This 
family-history (FH) based approach requires individuals/general practitioners to 
recognize and act on a clinically significant FH. Mutation carriers, who lack/are 
unaware of their FH, who do not recognize the risk associated with FH or are not 
proactive in seeking advice, are inevitably excluded.[10-12] Most of these current 
approach associated limitations could be overcome by systematic population-based 
testing. The literature indicates that genetic counseling/testing is associated with 
psychological benefits in non-carriers and has no substantial adverse psychological 
consequences for carriers.[8, 13] However, available data are predominantly from 
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trials in highly selected samples of individuals with a strong FH of cancer, and the 
results cannot be generalized to the general population. There is no established 
model for population-based testing of dominant mutations, and the best way to 
deliver this service on a population basis is unknown.[13]  
 
We describe results from the first phase of a novel randomized controlled trial( RCT): 
Genetic Cancer Prediction through Population Screening (GCaPPS). The objective 
was to assess the benefits/disadvantages of a population-based approach to genetic 
testing for high-penetrance dominant gene mutations compared to the conventional 
FH-based approach.  The RCT design provided a basis for comparison of 
psychological and quality-of-life differences between population-based and FH-
based testing. We based the trial in an Ashkenazi Jewish (AJ) community as a 
‘population-model’ and used BRCA1/2-mutations as our ‘disease-model’. These 
choices were guided by the higher prevalence of three BRCA1/2 founder-mutations 
in the AJ population. 
 
METHODS 
 
Design 
GCaPPS is a RCT (ISRCTN73338115) with two arms: population-screening (PS) 
arm, and family-history (FH) arm. Inclusion criteria were: age greater than 18 years 
and AJ ethnicity (self-reported history, 4-AJ grandparents). Exclusion criteria were: 
known BRCA mutation, first degree relative (FDR) of a BRCA carrier or previous 
BRCA testing. This article reports on (a) founder-mutations detected, (b) 
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acceptability of the test, and (c) psychological and quality-of-life impact. Further 
analysis of uptake of screening/preventive strategies is in progress. 
 
Participants 
Participants were recruited via the North-London Jewish community, following a 
broad-based consultation with key stakeholders of the AJ community and publicity 
about the program. 
 
Recruitment 
Recruitment was by self-referral. Study information/leaflets were made available 
through community charities, religious groups, a pharmacy chain (Boots) and web-
site (www.gcapps.org). Volunteers received structured, non-directive pre-test 
genetic-counseling for informed decision making between October 2008 and July 
2010 at six centers which included a popular high street pharmacy chain and Jewish 
charity community centers, thus providing counseling within a novel high-
street/community-based setting. Genetic counseling was undertaken by a qualified 
genetic counselor with supervision from a Regional Genetics Centre and a clinical 
fellow with substantial experience in cancer genetics risk assessment and 
management. It was structured to meet the goals of genetic counseling and cancer 
risk assessment. FH and baseline data were collected at initial appointment. 
Individuals deciding to undergo genetic testing were consented post-counseling. 
Randomization 
Consenting participants were randomized post-counseling using a computer 
generated random-number algorithm. Genetic counselors were blinded to group 
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allocation during counseling and recruitment. Participants were informed of their 
randomized allocation by mail. 
 
Genetic-analysis 
Genetic testing was performed on all PS-arm volunteers and only FH-arm volunteers 
fulfilling standard FH-based criteria (Table 1).  This involved sequencing analysis of 
BRCA1 exons 1 and 20 and a segment of BRCA2 exon 11 for three Jewish founder-
mutations:  185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 
6174delT(c.5946delT) in a NHS clinical genetics laboratory. Variants detected were 
reconfirmed using a separate aliquot of the original DNA sample.  We also obtained 
data on AJ BRCA carriers detected through London clinical genetics laboratories 
from 2000-2010. 
Test-result management  
Founder-mutation positive (and equivalent number of randomly selected founder-
mutation negative) individuals received their result at standard face-to-face post-test 
counseling. Mutation carriers were advised to request referral (via general-
practitioner) to a NHS regional genetics-clinic for confirmatory testing and access to 
established risk-management services. Founder-mutation negative volunteers who 
fulfilled standard non-AJ high-risk criteria (Table 1) were also referred to genetic 
clinics. All other founder-mutation negative volunteers obtained test results by mail.  
Assessment of demographic, psychosocial outcomes and Follow-up 
Socio-demographic and FH data were collected using a customized questionnaire. 
Depression and anxiety were assessed with the Hospital Anxiety and Depression 
Scale (HADS).[14] The SF12-questionnaire (Physical Health Component scale 
(PCS) and Mental Health Component scale (MCS)) was used to assess quality of 
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life.[15, 16] A very-short version of the Health-Anxiety Inventory (HAI),[17] was used 
to measure health anxiety. The impact of genetic test result disclosure was assessed 
with the distress, uncertainty, and positive-experience scales of the Multidimensional 
Impact of Cancer Risk Assessment (MICRA) questionnaire.[18] Data were collected 
at baseline (pre-counseling), immediately post-counseling (post-decision making), 
and at 7-days and, 3-months after getting the test result. Further follow up at 1, 2 and 
3 years is in progress. Details are accessible at http://www.controlled-
trials.com/ISRCTN73338115. FH-negative FH-arm participants who completed the 
study were offered testing at the end of 3-years follow-up. 
 
Trial Management 
A customized (prototype based [19, 20]) trial-management system was developed 
for running/managing the study. This included an automated randomization function 
for group allocation, access to pedigree data, volunteer flagging/tracking, electronic 
data upload/access and upgrade capability for protocol development. 
 
Statistical analysis 
Randomization of 1034 volunteers was completed in July 2010. The primary 
comparison is based on an intention-to-treat analysis between the PS and FH arms. 
Baseline characteristics were calculated using descriptive statistics.  
The questionnaire data were collected over 3 time-points and so to adequately deal 
with clustered-data (within individuals over time) a random-effects model (random 
intercept only) with robust standard-errors was used to evaluate the effect of the 
intervention (genetic testing) on outcome variables. The model included a group-
effect, time-effect and group-by-time interaction. The group-by-time interaction 
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indicates whether there is a difference in change over time between groups and 
represents the effect of intervention. Appropriate model-based tests/contrasts were 
used to investigate group and time differences. Contrast tests were used to compare 
difference between the groups over time points, specifically between time point 1 
versus time point 2 and between time point 1 versus time point 3, as well as an 
overall time effect between groups (contrast of all 3 time points), tested on 2 degrees 
of freedom. Additional covariates of interest were also included in the model: sex, 
age, FH, income and marital status. Predicted mean scale scores with 95% CI over 
all values of group and time were plotted, with other covariates set to their mean 
value. Statistical analyses used Stata-11.0 (Stata-Corp LP, Texas, USA) and R(R-
Project GNU General-Public-License, Austria,www.R-project.org).[21]  Two-sided p-
values are reported for all statistical tests.  
 
GCaPPS Phase 1 was powered to assess psychological outcomes. A sample size of 
509/arm had 90% power to detect a difference of 1.2 points in total HADS scores 
between the two groups assuming a common SD of 5.9 and α=0.05. 
 
RESULTS 
Between August 2008 and July 2010, 1615 people registered and 1168 attended 
genetic counseling. Of these, 8 (0.7%) were excluded: six FDR of BRCA carriers, 
two with <4 AJ grandparents. A total of 1042 (89%) consented to genetic testing of 
whom eight withdrew within three weeks, and 1034 (691 women, 343 men) were 
randomized to the PS (n=530) or FH (n=504) arms (Figure 1). Reasons for 
withdrawal (n=17) included: death (n=2), death of spouse (n=1), relocation (n=1), 
changed mind (n=4), not wishing to fill more questionnaires/continue (n=4), results 
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no longer felt relevant (n=2), none given (n=3).  A total of 1017 were eligible for 
analysis. 
 
FH and PS groups were comparable at baseline (Table 2). The mean age of 
participants was 54.3 (SD=14.66) years, 33.2% were men and 66.8% women. 
Thirteen (7BRCA1, 6BRCA2) carriers were detected in the PS arm 
(prevalence=2.45%,CI:1.31,4.16). Of these only 3 had a clinically significant FH (FH-
positive), indicating that 10/13 (77%) carriers in the PS arm would not have been 
detected by FH alone. Nine carriers (5 BRCA1, 4 BRCA2) were detected in the FH 
arm (prevalence=1.79%, CI:0.82,3.36%) (group difference: p=0.522). Five more 
carriers were detected among FH-negative FH-arm participants following study 
completion. 
 
The group-by-time interaction effect in the random effects model was not statistically 
significant for outcomes of anxiety, depression, quality of life, health anxiety, distress 
and uncertainty associated with genetic-testing (Tables 3,4). This indicates that there 
is no evidence that population-based genetic testing has different psychological or 
quality of life effects than a FH-based approach over time. The group-by-time 
interaction for positive experience was of borderline statistical significance (p=0.04), 
with scores being higher in the population screening arm and for men (Table 4). 
Modeling showed lower levels of anxiety and health anxiety in participants who were 
older (p=0.002) and with higher income (p<0.0005) and in men compared to women 
(p<0.0005),(Tables 3,4). Depression was also lower in higher income participants 
(p<0.0005),(Table 4). Being married and having higher incomes were associated 
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with statistically significantly lower levels of distress and uncertainty following genetic 
testing, but this was not affected by sex, age, or FH (Table 4),.  
 
Contrast tests indicated an overall decrease in anxiety (p=0.0001), distress (p=0.04), 
and  uncertainty (p=0.005) with time. The majority of decline in anxiety was observed 
in the baseline-7days (-0.64) rather than the 7days-3months (-0.24) period. Positive-
experience scores increased (p=0.0001), but quality-of-life and health-anxiety did not 
change with time. Predicted mean plots (Supplementary Figures1-9, available 
online) illustrate these effects. The mean HADS, SF12, HAI and MICRA scores at 
7days/3-months are given in Table 5.  
 
The overall BRCA1/2 prevalence detected was 2.45% (95% CI:1.31%,4.16%). Of the 
1034 participants 128 (12.4%, CI:10.4,14.5%) were FH positive. In our sample the 
population prevalence of FH-positive BRCA carriers (12/1034) was 1.16% 
(CI:0.60%,2.02%) and the population prevalence of BRCA carriers not fulfilling FH-
based criteria for testing (FH-negative,10/530) was 1.89% (CI:0.91%,3.44%). To 
date, 210 of the 438 FH-negative participants in the FH arm have completed 3 years 
of follow-up and subsequently opted for genetic testing. Five additional BRCA 
carriers (2 BRCA1, 3 BRCA2) have been detected in these 210 participants, giving a 
total BRCA prevalence of 15/740 or 2.03% (CI:1.14,3.32%) in FH-negative 
individuals. This indicates that a minimum of 15/27 (56%) carriers in this population 
are not detectable by the conventional FH approach, and this figure will rise when 
the remaining 218 FH-negative participants reach 3-year follow-up and are tested. 
The minimum proportion of carriers detectable by PS in the overall study population 
was therefore 27/1034 (prevalence=2.61%; CI:1.73,3.78%). For 27 BRCA carriers in 
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the population, the sensitivity of a FH-based approach is 44.4% (95%CI:26.4,63.9%) 
while the positive-(PLR) and negative-likelihood-ratios (NLR) are 3.86 
(95%CI:2.2,5.81) and 0.63 (95%CI:0.41,0.84) respectively. FH details of BRCA 
carriers are given in Supplementary Table 1. 
 
DISCUSSION 
 
To the best of our knowledge this is the first population-based RCT without 
ascertainment biased by cancer history in self/family, comparing FH and population-
based approaches for testing dominant gene disorders. While previous single-arm 
studies have suggested that population testing could detect more carriers than FH-
based testing, they were not designed or able to compare the psychological/quality-
of-life implications of population-based testing with the current standard of care. Our 
finding of no statistically significant short term differences between FH and 
population-based approaches with respect to levels of anxiety, depression, health 
anxiety, physical/mental well-being, distress, and uncertainty linked to genetic testing 
is reassuring. It confirms that population-based genetic testing in the majority of 
people does not harm quality of life or psychological well-being, or lead to excessive 
health concerns, and is similar to findings among individuals being tested using 
current clinical criteria.[8, 13, 22]  
 
That participation in the program was associated with decreases in anxiety and 
uncertainty linked to genetic testing is heartening. This is consistent with many 
earlier reports that identified important psychological benefits of testing [8, 13, 22, 
23] though a few reports have found increased distress.[24] A population-based 
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single arm study in unselected Canadian Jewish women undertaken around the 
same time as our study, reported increased levels of cancer related distress at one 
year in founder-mutation positive but not founder-mutation negative women. 
However, this was not a RCT and did not compare the FH and population-screening 
approaches to genetic testing. In addition none of the women received pre-test 
genetic-counseling though 93% expressed satisfaction with the testing process.[25] 
Data on long-term outcomes from GCaPPS participants are still being collected and 
will be reported in due course.  
 
This is the first report on factors affecting psychological health and quality-of-life 
following genetic testing for cancer predisposing genes in an unselected population 
of men and women. FH did not affect levels of general anxiety, health anxiety, 
depression, quality of life, or distress/uncertainty/experience specific to genetic 
testing (Tables 3,4). This finding is consistent with an earlier study [26] but contrary 
to another small study [27] reporting higher cancer-specific distress at 6-months in 
increased risk compared to average risk participants. In the latter, absolute levels of 
stress were not high and overall stress decreased with time.[27] Support provided by 
a spouse and higher income had a beneficial impact on anxiety and uncertainty. Our 
findings are largely in agreement with normative data from other populations [28-30] 
while few of the variations observed may reflect population-based differences in the 
Ashkenazi UK community. It is important to note that though the effects of a number 
of demographic variables on outcomes observed are statistically significant, they 
may reflect a large sample size. Given the modest absolute effect sizes, most are 
unlikely to be clinically relevant. 
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The decrease in uncertainty (MICRA [18]) specifically associated with genetic testing 
and the lack of difference between PS and FH groups reconfirms that testing in a 
low-risk population has similar benefits to testing of a high-risk population. The 
positive-experience scale is reverse scored and increase in scores with time may be 
related to the possibility of reducing family support or relief with the passage of time 
following receipt of test result. This increase was statistically significantly greater for 
men than women (p<0.0005) and in those in the population screening arm but not 
affected by age or FH. These data suggest that men and women may respond 
differently to the experience of receiving genetic-test results. It is possible that 
women and those with a strong FH feel more supported/relieved. This finding has 
not been reported before in a population-based setting. While the scores are useful 
for monitoring, the thresholds of clinical significance are unknown. The interpretation 
of these findings is limited by the MICRA development methodology which was 
based solely on a high-risk population that lacked men. Further research into 
developing and validating instruments specific to genetic testing in low-risk 
populations is warranted. 
 
At least 56% of carriers in our study population would not have been detected using 
traditional clinical criteria. This is also the first study to report and confirm that the UK 
prevalence of Jewish BRCA founder mutations is similar to findings from other 
regions.[10, 31] Our prevalence estimates for FH-positive (1.16%) and FH-negative 
(1.89%) carriers suggests that the proportion of undetectable carriers in the entire 
study population using FH alone could reach 63%. This finding is consistent with an 
initial Washington [10] study and with Canadian [32] and Israeli [33] single arm 
studies undertaken around the time of this trial, in which 40% [10], 55% [32], and 
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63% [33] of carriers, respectively, lacked a strong FH of cancer. It corroborates data 
on limited family structure [34] and reports from cancer case series unselected for 
FH, where 50%-75% of carriers lacked a clinically significant FH.[11, 12, 35-38] We 
estimate that many more carriers could be detected using a PS approach than by 
conventional FH-based testing (2.61% vs. 1.16%). Taken together, these data 
clearly illustrate the limitations of the current UK threshold for BRCA1/2 genetic 
testing. Lack of FH may be due to limited communication, lack of awareness, 
inaccuracies in FH, family lost in the Holocaust, family migration, small family size, 
paternal transmission, male preponderance, few women inheriting the mutation, and 
chance. 
 
If the current UK threshold for FH-based testing were relaxed to include a BRCA 
related cancer (breast/ ovary/ prostate) in a FDR <60 years, a FDR at any age, a 
second degree relative (SDR) < 60 years or a SDR at any age, then, 
correspondingly, a further 2, 4, 4 or 5 founder mutation carriers, respectively, would 
be re-classified as FH positive and detected from amongst the current 15 FH 
negative volunteers (Supplementary Table 1). However, this increase in sensitivity 
from 44.4% to 62.9% would be at the cost of decrease in specificity and a much 
lower threshold of BRCA probability for testing. 
 
The difference in number of FH-positive carriers between the FH (9/66) and PS 
(3/62) arms is likely to be explained by the small sample size and chance. The high 
population prevalence of carriers without a strong FH (1.89%) reveals a substantial 
at-risk population not detectable using currently available models/FH-based criteria. 
It suggests that a population-based approach to genetic-testing requires careful 
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consideration. Validation studies in high-risk populations show that BRCA risk-
prediction models are moderately effective in identifying carriers (AUC,0.67-0.8), 
poor at ruling out the presence of a mutation [39], underestimate the probability of 
detecting mutations at low(≤10%), and intermediate (10-40%) probability levels, and 
over-estimate mutations at high-probability thresholds [40-42]. Our findings of a 
PLR=3.8 and an NLR=0.63, reconfirm the poor ability of FH to detect BRCA carriers 
or rule out the presence of a mutation in a population-based cohort. Should the 
number of carriers be >27, the PLR would be even lower and NLR even higher. For 
comparison the PLR/NLR for mammography is 9.4/0.19 [43].  
 
312 BRCA carriers (51% via predictive testing, 49% new mutations) were detected 
from 2000-2010 through London NHS laboratories using FH-based criteria. The total 
estimated London AJ BRCA carriers eligible for testing (2.45% of 105,600 estimated 
AJ population >18 years) is 2587. Over a period of 10 years only 12% of these have 
been identified. Although this figure excludes some private sector testing, most 
genetic testing in the UK is undertaken within the NHS. Given the options that now 
exist for cancer risk management and prevention this raises questions about the 
current FH-based approach for identifying people at risk and makes it imperative to 
explore new approaches for risk prediction.  The optimal approach adopted will also 
need to take into account the cost of case identification.  
 
There is reasonable acceptability of BRCA testing among interested community 
members. Almost three-quarters (72%) of those expressing an interest attended 
counseling and the majority (89%) consented to testing. Our study has several 
advantages, including the randomized design, high questionnaire response rates, 
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and pre-test genetic counseling received by participants. We successfully provided 
counseling within a novel community and high-street based setting, away from the 
traditional hospital base. Recently reported population studies were single-arm and 
offered counseling only post-testing.[32, 33] Both men and women participated in 
GCaPPS and the results give an initial estimate of the distribution of people who may 
come forward should BRCA testing be offered on a population basis. In keeping with 
this, the prevalence of psychiatric morbidity, [44] levels of anxiety, depression [45] 
and quality-of-life [28, 29] in our cohort (Table 2) are similar to reports from UK 
population-based surveys.[44]  
 
While the initial results from our study are promising, the study is limited by the small 
number of carriers and the short term follow-up.  Some important questions 
highlighted above remain to be answered and longer-term follow-up data evaluated 
before committing substantial resources to population-based genetic testing. We 
have not had sufficient power to examine differences in psychological impact or 
behavioral outcomes (uptake of screening/preventive options) between BRCA-
carriers detected through FH and population-based approaches. These issues will 
be addressed in the next phase of the trial. Participants in our study had higher 
income and education levels, but this is consistent with the income/education levels 
found in the UK Jewish population compared to the general population.  
 
There remains some debate on whether mutations detected in the setting of a family-
history will have greater risk than those detected in a population without family-
history. Penetrance estimates may be upwardly biased for mutation carriers in the 
presence of residual familial aggregation if the analytic method assumes that 
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disease risk depends on mutation status only. Data from the population-based 
Washington Ashkenazi Study corrected for ascertainment, [46-48] meta-analysis of 
population/case-series based data [2], and, more recently, penetrance estimates 
from a single arm Israeli study [33] (corrected for previous potential biases of 
estimates derived mainly from female carriers) indicate that Jewish BRCA1/BRCA2 
carriers ascertained on a population basis and those without a strong family-history 
of cancer have high risks for breast/ovarian cancer, though these estimates are 
clearly lower than estimates obtained from high-risk families/cancer genetic clinics. 
 
The whole issue of cancer risk estimation/penetrance is complex, and current 
estimates used in clinical practice are derived from models which do not incorporate 
a number of epidemiologic and/or genetic variables which can modify risk.  The 
complexities and limitations around risk estimation were addressed via individualized 
pre-test genetic counseling undertaken by counselors with considerable experience 
in cancer risk estimation. While the baseline risk estimates used were based on 
those corrected for population based ascertainment, the volunteer’s family history 
was reviewed and taken into account during this process. 
 
New gene sequencing technologies [49] and the falling cost of genetic testing may 
make it economically feasible to test large populations in the future.  However, a 
number of issues related to sensitivity, specificity, variants of undetermined 
significance and non-zero error rate linked to new testing technologies need further 
clarifying and resolving before such an approach can be assessed in the non-AJ 
general population. Our study is limited by being specific to the Jewish community 
and hence, our findings on uptake, psychological impact, and quality-of-life cannot 
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be directly extrapolated/applied to the general non-AJ population. While applicability 
of such an approach to the general non-AJ population requires more research, our 
findings are relevant to and carry an important message for impact of population 
based testing in Ashkenazi Jews. The lack of detrimental psychological/quality-of-life 
outcomes coupled with a health economic benefit found in our decision-analytic 
model has important policy implications for the AJ population, which can save lives. 
This will require a change in the current paradigm of a FH-based approach to genetic 
testing in this population. Efficient, acceptable and more cost-effective ways of 
delivering information on genetic risk on a population basis will also be necessary for 
this and require future research.   
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Table 1. High Risk Criteria 
 
AJ High Risk Criteria for FH positive group (used in clinical genetics units) 
Volunteer should fulfill any one of the following criteria. (Volunteer / proband should 
either have been affected by cancer or be a first degree relative (FDR) of an affected 
family member).  
1) FDR with breast cancer (<50 years)  
2) FDR with ovarian cancer* (any age)  
3) Personal history of breast cancer (<50 years)  
4) Personal history of ovarian cancer* (any age) 
5) FDR with Male Breast Cancer (MBC) (any age) 
6) Personal history (men) of MBC (any age) 
*Equivalence of history of ovarian/ primary peritoneal cancer (PPC)/ fallopian tube 
cancer (FTC) for HR criteria 
Extended High-risk criteria for referral of FM negative volunteers to the regional 
genetic units  
Volunteer should fulfil any one of the following criteria. (Volunteer /proband should 
either have been affected by cancer or be a FDR of an affected family member. Criteria 
should be fulfilled on the same side of the family) 
Families with ovarian* cancer (HOC) or breast and ovarian*cancer (HBOC) 
1) ≥2 individuals with ovarian cancer* who are FDR 
2) One ovarian cancer* and 1 breast cancer <50 years who are FDR 
3) One ovarian cancer* and 2 breast cancers <60 years who are FDR 
4) Criteria 1, 2, and 3 can be modified where paternal transmission is occurring i.e. 
families where affected relatives are related by second degree through an unaffected 
intervening male relative and there is an affected sister are eligible. 
5) Breast cancer in volunteer/ proband (≤50 years) and mother (or sister) with both 
breast and primary ovarian cancer* (in the same person)  
Families with Breast cancer only (HBC) 
6) Breast cancer in volunteer/ proband (≤50 years) and any one of the following- 
a) breast cancer in mother (age of onset being ≤30 years in one and ≤50 years in 
the other) or  
b) b/l breast cancer in mother or sister (≤50 years onset of first) 
7) ≥4 breast cancers  
8) 3 breast cancers related by FDR and 
a) one ≤30 years or  
b) two ≤40 years (and all ≤60 years) or  
c) one MBC (≤60 years) and other two ≤50years 
Male Breast Cancer (MBC) 
9) Two MBC (≤60 years) in the family and proband is a FDR of one of them 
Mutation Positive families 
10) Known non-FM in the family 
11) Known history of mutation in the family, though unable to trace/ identify exact 
pathogenic mutation and testing negative for 3 FM.  
*Equivalence of history of ovarian/ PPC/ FTC for HR criteria  
**Cases of b/l breast cancer- each breast cancer may have same count as one relative 
AJ- Ashkenazi Jewish; b/l – bilateral; FH- family history; FM- founder mutation; FTC- 
fallopian tube cancer; HR- high risk; MBC- male breast cancer; PPC- primary 
peritoneal cancer
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Table 2. Baseline Characteristics of Population Screening and Family History 
arms 
Characteristic FH (n=504) PS (n=530) 
 Age Mean Age in years (S.D) 54.30 (14.31) 54.30 (14.99) 
Marital 
Status 
Single 9.4% 9.0% 
Married 75.5% 75.5% 
Cohabiting (living-with-partner) 4.0% 4.4% 
Divorced/ Separated 5.6% 6.1% 
Widowed 5.4% 5.0% 
Children Have children 81.2% 82.4% Number of children (S.D) 2.3 (1.28) 2.27 (1.3) 
Gender Men 32.1% 34.2% Women 67.9% 65.8% 
Education 
No-Formal- Qualification 6.8% 7.6% 
GCSE, O-level, CSE 20.7% 17.4% 
NVQ1,NVQ2 1.2% 1.4% 
A-level,NVQ-3 10.2% 11.8% 
NVQ-4 2.5% 1.2% 
Bachelors 37.1% 40.7% 
Masters 16.8% 15.6% 
PhD 4.7% 4.4% 
Income (£) 
<10,000 4.3% 5.1% 
10,000-19,900 7.2% 8.5% 
20,000-29,900 9.7% 9.6% 
30,000-39,900 12.7% 13.0% 
40,000-49,900 12.9% 10.9% 
≥50,000 53.2% 52.9% 
Affiliation / 
Identity 
Unaffiliated 15.6% 14.0% 
Liberal 10.2% 8.2% 
Reform 16.0% 15.1% 
Traditional 25.5% 24.9% 
Conservative/ Masorti 10.0% 8.2% 
Orthodox 22.6% 29.5% 
FH FH Positive (AJ Criteria)* 13.1% 11.7% 
FH FH Positive (Extended Non-AJ Criteria)† 3.2% 3.0% 
Psychiatric 
History 
h/o Depression 12.9% 12.9% 
h/o any psychiatric illness 5.7% 4.3% 
h/o medication for Psychiatric 
condition 17.0% 14.4% 
Current medication for 
Psychiatric condition 4.9% 6.4% 
 
AJ- Ashkenazi Jewish; FH- family history; NVQ- National Vocational Qualification; 
PS- population screening; S.D- standard deviation; h/o = history of. 
*AJ Criteria: High-risk Ashkenazi Jewish criteria (used for Randomization), Table 1 
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†Non-AJ Criteria: Extended high-risk criteria for the general population, see Table 1
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Table 3. Random Effect Models for difference in psychological and quality of 
life outcomes between FH and PS groups over time  
 
RANDOM EFFECTS MODEL for HADS     
HADS Total Coef. Std. Err  P>|z| [95% CI] 
Group -0.472 0.344 0.169 -1.146, 0.201 
Occasion 2 -0.473 0.484 0.328 -1.422, 0.475 
Occasion 3 -0.881 0.740 0.234 -2.331, 0.570 
Group#Occasion         
1 2 -0.473 0.484 0.328 -1.422, 0.475 
1 3 -0.881 0.740 0.234 -2.331, 0.570 
Sex -1.292 0.360 <0.0005 -1.997, -0.587 
FH 0.651 0.506 0.198  -0.341, 1.643 
Age -0.035 0.011 0.002 -0.057, -0.013 
Income -0.544 0.128 <0.0005 -0.795, -0.293 
Marital Status 0.556 0.460 0.227  -0.345, 1.458 
HADS Depression Coef. Std. Err  P>|z| [95% CI] 
Group -0.220 0.166 0.184 -0.545, 0.105 
Occasion 2 0.114 0.309 0.711 -0.491, 0.719 
Occasion 3 -0.141 0.392 0.718 -0.910, 0.627 
Group#Occasion         
1 2 -0.330 0.323 0.307 -0.962, 0.303 
1 3 -0.108 0.405 0.790  -0.901, 0.685 
Sex -0.166 0.173 0.337 -0.505, 0.173 
FH 0.345 0.253 0.173 -0.151, 0.840 
Age -0.002 0.005 0.710 -0.012, 0.008 
Income -0.254 0.064 <0.0005 -0.379   -0.129 
Marital Status 0.267 0.223 0.232 -0.171, 0.705 
HADS Anxiety Coef. Std. Err  P>|z| [95% CI] 
Group -0.252 0.228 0.270 -0.699, 0.196 
Occasion 2 -0.584 0.325 0.072 -1.220, 0.0526 
Occasion 3 -0.738 0.434 0.089 -1.589, 0.113 
Group#Occasion         
1 2 -0.126 0.350 0.719 -0.811, 0.560 
1 3 -0.315 0.457 0.491 -1.210, 0.580 
Sex -1.129 0.231 <0.0005 -1.582, -0.676 
FH 0.305 0.334 0.361 -0.349, 0.959 
Age -0.033 0.008 <0.0005 -0.048, -0.018 
Income -0.288 0.081 <0.0005 -0.447, -0.130 
Marital Status 0.285 0.293 0.331 -0.289, 0.860 
RANDOM EFFECTS MODEL for SF12     
SF12- MCS Coef. Std. Err  P>|z| [95% CI] 
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Group 0.373 0.356 0.295 -0.325, 1.071 
Occasion 2 0.493 0.734 0.502 -0.945, 1.932 
Occasion 3 -0.289 0.690 0.676 -1.641, 1.064 
Group#Occasion         
1 2 -0.647 0.784 0.409 -2.183, 0.889 
1 3 -0.058 0.734 0.937 -1.496, 1.381 
Sex 0.480 0.325 0.141 -0.158, 1.117 
FH -1.007 0.531 0.058 -2.047, 0.033 
Age 0.081 0.011 0.000 0.059, 0.102 
Income 0.084 0.120 0.481 -0.151, 0.319 
Marital Status 0.994 0.453 0.028 0.106, 1.882 
SF12- PCS Coef. Std. Err  P>|z| [95% CI] 
Group 0.193 0.330 0.558 -0.453, 0.839 
Occasion 2 0.634 0.625 0.311 -0.592, 1.859 
Occasion 3 0.619 0.606 0.307 -0.568, 1.807 
Group#Occasion         
1 2 -0.797 0.669 0.233 -2.108, 0.514 
1 3 -0.877 0.651 0.178 -2.154, 0.399 
Sex 1.656 0.301 <0.0005 1.066, 2.246 
FH 0.344 0.465 0.460 -0.568, 1.256 
Age -0.092 0.011 <0.0005 -0.115, -0.070 
Income 0.361 0.113 0.001 0.139, 0.583 
Marital Status 0.080 0.415 0.846 -0.733, 0.894 
 
The group-by-time interaction was not statistically significant for any of the models 
Coef: coefficient; Err: Error; FH: family history; HADS -  Hospital Anxiety and 
Depression Scale; PS- population screening; SF12 PCS- SF12 quality-of-life 
Physical component scale; SF12 MCS – SF12 quality-of-life Mental component 
scale; QoL – quality of life; Std: standard 
Group#Occasion- Group-by-time interaction effect 
Reference category for variables is denoted by * 
*Group 0=FH (family history); Group 1=PS (population screening); *Occasion 
1=baseline; Occasion 2= Time point 2 (7days post test result); Occasion 3= Time 
point 3 (3 months post test result); *Sex 0=female; Sex 1=male; *FH 0=low risk; FH 
1=high risk;  
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*Marital Status 0=live alone i.e single/divorced/widowed; Marital Status 1=live with 
partner i.e married/cohabiting 
Income- as ‘continuous variable’, but measured in £10,000 increments 
Age – in years (continuous variable) 
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Table 4: Random Effects Models for health anxiety (HAI), distress, uncertainty 
and positive experience (MICRA) outcomes 
 
RANDOM EFFECTS MODEL for HAI 
HAI Coef. Std. Err   z     P>|z| [95% CI] 
Group -0.088 0.171 -0.510 0.609 -0.423, 0.248 
Occasion_2 0.167 0.279 0.600 0.549 -0.380, 0.715 
Occasion_3 -0.037 0.360 -0.100 0.918 -0.743, 0.669 
Group#Occasion†           
1 2 0.019 0.295 0.060 0.949 -0.561, 0.598 
1 3 0.090 0.372 0.240 0.810 -0.641, 0.820 
Sex -0.486 0.165 -2.950 0.003 -0.809, -0.163 
FH 0.097 0.271 0.360 0.721 -0.434, 0.629 
Age -0.011 0.006 -2.040 0.042 -0.023, -0.0004 
Marital Status 0.245 0.213 1.150 0.251 -0.173, 0.663 
Income -0.153 0.061 -2.500 0.012 -0.272, -0.033 
RANDOM EFFECTS MODEL for MICRA 
MICRA Distress Coef. Std. Err   z     P>|z| [95% CI] 
Group -0.790 0.853 -0.930 0.354 -2.461, 0.881 
Occasion_3 -1.159 0.682 -1.700 0.089  -2.495, 0.177 
Group#Occasion‡           
1 3 0.945 0.691 1.370 0.172 -0.410, 2.301 
Sex -0.010 0.205 -0.050 0.962  -0.411, 0.392 
FH 0.537 0.494 1.090 0.278  -0.432, 1.506 
Age -0.009 0.010 -0.890 0.376 -0.028, 0.10 
Marital Status 0.331 0.113 2.91 0.004  0.108, 0.553 
Income -0.216 0.109 -1.98 0.047 -0.430, -0.002 
MICRA 
Uncertainty Coef. Std. Err   z     P>|z| [95% CI] 
Group 0.062 1.127 0.060 0.956 -2.148, 2.272 
Occasion_3 -0.474 0.651 -0.730 0.466 -1.750, 0.802 
Group#Occasion‡           
1 3 -0.133 0.680 -0.200 0.845 -1.466, 1.199 
Sex -0.389 0.398 -0.980 0.328 -1.169, 0.391 
FH 1.359 0.762 1.780 0.075 -0.135, 2.853 
Age 0.003 0.017 0.210 0.836 -0.029, 0.036 
Marital Status 0.635 0.225 2.83 0.005 0.195, 1.076 
Income -0.418 0.18 -2.32 0.02 -0.771, -0.065 
MICRA Positive 
Experience Coef. Std. Err   z     P>|z| [95% CI] 
Group -1.509 1.078 -1.400 0.162 -3.622, 0.604 
Occasion_3 0.915 0.936 0.980 0.328 -0.919, 2.749 
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Group#Occasion‡           
1 3 2.078 1.010 2.060 0.040 0.097, 4.059 
Sex 3.370 0.607 5.550 <0.0005 2.18, 4.56 
FH -0.746 0.738 -1.010 0.312 -2.193, 0.700 
Age -0.019 0.021 -0.900 0.369 -0.062, 0.023 
Marital Status -0.297 0.317 -0.94 0.349 -0.918, 0.325 
Income -0.016 0.177 -0.09 0.927 -0.364, 0.331 
 
The group-by-time interaction was not significant for HAI, MICRA-distress or MICRA-
uncertainty models, but was of borderline significance for MICRA-positive experience 
model 
Coef: coefficient; Err: Error; FH: family history; HAI - Health Anxiety Inventory scale; 
MICRA- Multidimensional Impact of Cancer Risk Assessment scale; PS- population 
screening; REM- Random Effects Model; Std: standard 
Group#Occasion- Group-by-time interaction effect 
Reference category for variables is denoted by * 
*Group 0=FH (family history); Group 1=PS (population screening); Occasion 
1=baseline; Occasion 2= Time point 2 (7days post test result); Occasion 3= Time 
point 3 (3 months post test result); *Sex 0=female; Sex 1=male; *FH 0=low risk; FH 
1=high risk; *Marital Status 0=live alone i.e single/divorced/widowed; Marital Status 
1=live with partner i.e married/cohabiting; Income- as ‘continuous variable’, but 
measured in £10,000 increments; Age – in years (continuous variable) 
†Occasion 1 is the reference variable for HAI random effects model and ‡Occasion 2 
is the reference for MICRA random effects model. 
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Table 5: Mean HADS, SF12, HAI and MICRA scores at baseline, 7 days and 3 months 
follow up by group 
 
 
  Mean Scores FH (n=504) PS (n=530) 
HADS HADS Total BL (S.D) 9.1 (5.3) 8.8 (5.25) 
  HADS Total 7d (S.D) 9.64 (5.04) 7.59 (5.15) 
  HADS Total 3mth (S.D) 9.12 (6.16) 7.3 (5.23) 
  HADS Anxiety BL  (S.D) 6.16 (3.46) 6.01 (3.61) 
  HADS Anxiety 7d (S.D) 6.04 (3.4) 5.16 (3.42) 
  HADS Anxiety 3mth (S.D) 5.9 (3.72) 4.8 (3.38) 
  HADS Depression BL (S.D) 2.94 (2.55) 2.78 (2.45) 
  HADS Depression 7d (S.D) 3.61 (2.76) 2.44 (2.48) 
  HADS Depression 3mth (S.D) 3.22 (3.01) 2.5 (2.55) 
SF12 
QoL SF12 Physical Scale BL (S.D) 49.17 (5.15) 49.22 (5.08) 
  SF12 Physical Scale 7d (S.D) 49.13 (5.13) 49.01 (5.11) 
  SF12 Physical Scale 3mth (S.D) 48.88 (5.41) 48.83 (5.46) 
  SF12 Mental Scale  BL (S.D) 52.14 (5.44) 52.28 (5.49) 
  SF12 Mental Scale  7d (S.D) 52.42 (5.28) 52.55 (5.10) 
  SF12 Mental Scale  3mth (S.D) 52.16 (5.08) 52.34 (4.95) 
vsHAI vsHAI score BL (S.D) 3.1 (2.63) 3.08 (2.51) 
  vsHAI score 7d (S.D) 3.45 (2.72) 3.18 (2.6) 
  vsHAI score 3mth (S.D) 3.71 (2.61) 2.99 (2.47) 
MICRA MICRA Distress score 7d (S.D) 1.8 (4.43) 0.78 (2.7) 
  MICRA Uncertainty score 7d (S.D) 4.4 (5.97) 2.98 (4.78) 
  MICRA Positive Experiences score 7d (S.D) 6.25 (5.49) 6.13 (6.03) 
  MICRA Distress score 3mth (S.D) 1.04 (2.08) 0.59 (2.28) 
  MICRA Uncertainty score 3mth (S.D) 3.71 (4.94) 2.22 (4.39) 
  MICRA Positive Experiences score 3mth (S.D) 7.42 (6.81) 9.06 (7.2) 
 
BL- baseline, FH- family history, PS- population screening, S.D – Standard 
Deviation, 7d- 7 days, 3mth- 3 months; HADS -  Hospital Anxiety and Depression 
Scale; HAI - Health Anxiety Inventory; SF12 QoL- SF12 quality-of-life scale; MICRA- 
Multidimensional Impact of Cancer Risk Assessment scale  
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Figure 1- Consort flow chart for the study 
 
BL- baseline; d- days; DNA- did not attend; FH- family history, FM- founder 
mutations; GC- genetic counseling; m- months; Neg- negative; PS- population 
screening, Pos- positive.  
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